However, patients with
drug-eluting stents may be prescribed the antiplatelet for a year or more, Dr.
Differences in safety profile between second generation
drug-eluting stents. Subgroup analysis at 2 years from the ESTROFA-2 Spanish registry.
Elevated levels of very low-density lipoprotein cholesterol independently associated with in-stent restenosis in diabetic patients after
drug-eluting stent implantation.
Lee et al., "Incidence and predictors of
drug-eluting stent fractures in long coronary disease," International Journal of Cardiology, vol.
Though
drug-eluting stents are becoming much more commonly implanted than bare-metal types, a BMS may be a more appealing option if the patient has a very high risk of bleeding or if a physician believes the patient won't be able to adhere to DAPT over a period of months or years.
Late stent malapposition risk is higher after
drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis.
ADAPT-DES is the largest study ever to explore the overall treatment implications of platelet reactivity on patient outcomes after successful coronary
drug-eluting stent implantation.
There is controversy over whether the
drug-eluting stent or the bare metal stent has superior clinical benefit.
According to the Natick, Mass.-based cardiovascular device giant, the devices are the only
drug-eluting stent (DES) systems in the United States with an approved indication to treat patients with AMI.
A
drug-eluting stent is a peripheral or coronary stent (a scaffold) placed into narrowed, diseased peripheral or coronary arteries that slowly releases a drug to block cell proliferation.
The Food and Drug Administration has approved the Xience V
drug-eluting stent, with the requirement that the manufacturer conduct postmarketing studies, including one that follows rates of stent thrombosis and other events in recipients for 5 years.
Key Words:
drug-eluting stent, complications, perioperative complications, myocardial infarction, perioperative clopidogrel